版本:
中国

BRIEF-Cerenis Therapeutics says primary endpoint not met in CARAT phase 2 study

March 20 Cerenis Therapeutics Holding SA :

* Cerenis therapeutics announces that CARAT phase 2 study data on CER-001 have been presented at ACC annual meeting 2017

* Primary endpoint, regression of coronary plaque in ACS, not met

* Safety profile of CER-001 is reinforced

* Tango phase 3 clinical study in patients with genetic HDL deficiencies is ongoing

* Negative results encountered with CER-001 were not consistent with previously reported efficacy profile of CER-001 in 3mg/kg subgroup of chi square clinical study Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐